Search Results - "Lu, Karen L."

Nonionic Polymers Reverse Inactivation of Surfactant by Meconium and Other Substances by TAEUSCH, H. WILLIAM, LU, KAREN W, GOERKE, JON, CLEMENTS, JOHN A

“…A variety of substances including human meconium have been found to affect adversely the surface tension-lowering activity of pulmonary surfactants, and this…”
Get full text

Polyethylene Glycol/Surfactant Mixtures Improve Lung Function after HCl and Endotoxin Lung Injuries by LU, KAREN W, TAEUSCH, H. WILLIAM, ROBERTSON, BENGT, GOERKE, JON, CLEMENTS, JOHN A

“…Addition of nonionic polymers such as polyethylene glycol (PEG) and dextran ameliorates inactivation of Survanta by a variety of substances in vitro. Addition…”
Get full text

Polymer-Surfactant Treatment of Meconium-induced Acute Lung Injury by LU, KAREN W, WILLIAM TAEUSCH, H, ROBERTSON, BENGT, GOERKE, JON, CLEMENTS, JOHN A

“…Substances (for example, serum proteins or meconium) that interfere with the activity of pulmonary surfactant in vitro may also be important in the…”
Get full text

Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response by DONG LIANG, MEYER, Larissa, CHANG, David W, JIE LIN, XIA PU, YUANQING YE, JIAN GU, XIFENG WU, KAREN LU

“…MicroRNAs (miRNA) play important roles in tumorigenesis. Genetic variations in miRNA processing genes and miRNA binding sites may affect the biogenesis of…”
Get full text

Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer by NANJUNDAN, Meera, NAKAYAMA, Yasuhisa, MILLS, Gordon B, KWAI WA CHENG, LAHAD, John, JINSONG LIU, KAREN LU, KUO, Wen-Lin, SMITH-MCCUNE, Karen, FISHMAN, David, GRAY, Joe W

“…Increased copy number involving chromosome 3q26 is a frequent and early event in cancers of the ovary, lung, head and neck, cervix, and BRCA1 positive and…”
Get full text

Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning by Basen-Engquist, Karen, PhD, MPH, Scruggs, Stacie, MPH, Jhingran, Anuja, MD, Bodurka, Diane C., MD, Lu, Karen, MD, Ramondetta, Lois, MD, Hughes, Daniel, PhD, Carmack Taylor, Cindy, PhD

“…Objective This study aims to determine the prevalence of physical activity and obesity and their relationship to physical functioning (PF), fatigue, and pain…”
Get full text

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations by JANKU, Filip, WHELER, Jennifer J, LUTHRA, Rajyalakshmi, LEE, J. Jack, LU, Karen H, KURZROCK, Razelle, WESTIN, Shannon N, MOULDER, Stacy L, NAING, Aung, TSIMBERIDOU, Apostolia M, SIQING FU, FALCHOOK, Gerald S, HONG, David S, GARRIDO-LAGUNA, Ignacio

“…Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant…”
Get full text

Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative by WOOD, Marie E, KADLUBEK, Pamela, PHAM, Trang H, WOLLINS, Dana S, LU, Karen H, WEITZEL, Jeffrey N, NEUSS, Michael N, HUGHES, Kevin S

“…Family history of cancer (CFH) is important for identifying individuals to receive genetic counseling/testing (GC/GT). Prior studies have demonstrated low…”
Get full text

American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers by LU, Karen H, WOOD, Marie E, RUBINSTEIN, Wendy S, STOFFEL, Elena M, SNYDER, Carrie, SYNGAL, Sapna, MERRILL, Janette K, WOLLINS, Dana Swartzberg, HUGHES, Kevin S, DANIELS, Molly, BURKE, Cathy, FORD, James, KAUFF, Noah D, KOHLMANN, Wendy, LINDOR, Noralane M, MULVEY, Therese M, ROBINSON, Linda

Get full text

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma by Slomovitz, Brian M., Lu, Karen H., Johnston, Taren, Coleman, Robert L., Munsell, Mark, Broaddus, Russell R., Walker, Cheryl, Ramondetta, Lois M., Burke, Thomas W., Gershenson, David M., Wolf, Judith

“…BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase…”
Get full text

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer by HENNESSY, Bryan T. J, TIMMS, Kirsten M, YANG LI, JIE LI, GONZALEZ-ANGULO, Ana Maria, MCCUNE, Karen Smith, MARKMAN, Maurie, BROADDUS, Russell R, LANCHBURY, Jerry S, LU, Karen H, MILLS, Gordon B, CAREY, Mark S, GUTIN, Alexander, MEYER, Larissa A, FLAKE, Darl D, ABKEVICH, Victor, POTTER, Jennifer, PRUSS, Dmitry, GLENN, Pat

“…The prevalence of BRCA(1/2) mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of…”
Get full text

Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study by BODURKA, Diane C, DEAVERS, Michael T, BAERGEN, Rebecca, EMERSON, Robert E, STEINHOFF, Margaret, BEHMARAM, Behnaz, RASTY, Golnar, GERSHENSON, David M, CHUNQIAO TIAN, SUN, Charlotte C, MALPICA, Anais, COLEMAN, Robert L, LU, Karen H, SOOD, Anil K, BIRRER, Michael J, OZOLS, Robert

“…A study was undertaken to use the 2-tier system to reclassify the grade of serous ovarian tumors previously classified using the International Federation of…”
Get full text

Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial by Moore, Lee E., Pfeiffer, Ruth M., Zhang, Zhen, Lu, Karen H., Fung, Eric T., Bast, Robert C.

“…BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I‐II), the 5‐year survival rate is between 70% and 90%; whereas, when it is detected…”
Get full text

Endometrial biomarkers in premenopausal obese women: an at-risk cohort by DOTTINO, Joseph A., ZHANG, Qian, LOOSE, David S., FELLMAN, Bryan, MELENDEZ, Brenda D., WATERS, Mikayla S., MCKENZIE, Laurie J., YUAN, Ying, YANG, Richard K., BROADDUS, Russell R., LU, Karen H., SOLIMAN, Pamela T., YATES, Melinda S.

Get full text

Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age by Moore, Richard G., MD, Miller, Michael Craig, BSN, Eklund, Elizabeth E., BSN, Lu, Karen H., MD, Bast, Robert C., MD, Lambert-Messerlian, Geralyn, PhD

“…Objective The purpose of this study was to establish normal ranges for human epididymis protein 4 (HE4) serum levels in healthy women. Study Design HE4 levels…”
Get full text

Testing Women With Endometrial Cancer to Detect Lynch Syndrome by KWON, Janice S, SCOTT, Jenna L, BLAKE GILKS, C, DANIELS, Molly S, SUN, Charlotte C, LU, Karen H

“…Women with endometrial cancer as a result of Lynch syndrome may not be identified as such by Amsterdam II criteria. We estimated the costs and benefits of…”
Get full text

Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders by Moore, Richard G., MD, Miller, Michael Craig, BSN, Steinhoff, Margaret M., MD, Skates, Steven J., PhD, Lu, Karen H., MD, Lambert-Messerlian, Geralyn, PhD, Bast, Robert C., MD

“…Objective The human epididymis protein 4 (HE4) is a novel biomarker for ovarian cancer. This study measured the HE4 and CA125 levels in women with benign…”
Get full text

Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations: Missed Opportunities by Meyer, Larissa A., Anderson, Meaghan E., Lacour, Robin A., Suri, Anuj, Daniels, Molly S., Urbauer, Diana L., Nogueras-Gonzalez, Graciela M., Schmeler, Kathleen M., Gershenson, David M., Lu, Karen H.

“…To estimate the incidence of genetic counseling referral for ovarian cancer patients who are at substantial risk for a BRCA1 or BRCA2 mutation. An analysis was…”
Get full text

Prospective Determination of Prevalence of Lynch Syndrome in Young Women With Endometrial Cancer by LU, Karen H, SCHORGE, John O, RODABAUGH, Kerry J, DANIELS, Molly S, SUN, Charlotte C, SOLIMAN, Pamela T, WHITE, Kristin G, LUTHRA, Rajyalakshmi, GERSHENSON, David M, BROADDUS, Russell R

“…Age younger than 50 years at the time of colon cancer diagnosis is often used as a screening criterion for Lynch syndrome (hereditary nonpolyposis colorectal…”
Get full text

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer by WESTIN, Shannon N., FELLMAN, Bryan, SUN, Charlotte C., BROADDUS, Russell R., WOODALL, Misty L., PAL, Navdeep, URBAUER, Diana L., RAMONDETTA, Lois M., SCHMELER, Kathleen M., SOLIMAN, Pamela T., FLEMING, Nicole D., BURZAWA, Jennifer K., NICK, Alpa M., MILBOURNE, Andrea M., YUAN, Ying, LU, Karen H., BODURKA, Diane C., COLEMAN, Robert L., YATES, Melinda S.

Get full text